Jiangxi Fushine Pharmaceutical Co., Ltd. Class A

Jiangxi Fushine Pharmaceutical Co., Ltd. Class A

SSZSE:300497
13.20
CNY
+0.01
(+0.08%)
0.74EPS
23.41P/E
9.62BMarket Cap
May 03Next Earn

Total Valuation

CNY

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A carries a market capitalization of 9.62B, placing it among publicly traded companies globally. Its enterprise value stands at 10.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap9.62B
Enterprise Value10.57B

Important Dates

Jiangxi Fushine Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for May 3, 2027.

Earnings Date5/3/2027

Share Statistics

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A has 538.65M shares outstanding.

Shares Outstanding538.65M

Valuation Ratios

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 23.41. The price-to-sales ratio is 4.89, and the price-to-book ratio stands at 3.75.

PE Ratio23.41
PS Ratio4.89
PB Ratio3.75
P/TBV Ratio4.24

Enterprise Valuation

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 24.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.57B versus a market cap of 9.62B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.38
EV / EBITDA24.02
EV / EBIT24.02

Financial Position

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.75, indicating elevated leverage, while an interest coverage ratio of 8.55 demonstrates adequate ability to service its debt obligations.

Current Ratio1.52
Quick Ratio0.40
Debt / Equity56.75
Debt / EBITDA3.33
Interest Coverage8.55

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 17.33, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.09 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.80, useful for judging operating efficiency across full business cycles. The company generates approximately 1.18M in revenue per employee across its workforce of 1,663.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.67 indicates how many times Jiangxi Fushine Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)17.33
Return on Assets (ROA)8.83
Return on Invested Capital (ROIC)10.09
Return on Capital Employed (ROCE)11.80
Revenue Per Employee1.18M
Employee Count1,663.00
Inventory Turnover2.67

Taxes

CNY

Over the twelve months ended September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A recorded 35.58M in income tax expense. That works out to an effective tax rate of 8.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 436.17M, leaving 410.62M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax35.58M
Effective Tax Rate8.16

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A's stock has declined approximately 37.59% over the past 52 weeks. The 50-day moving average sits at 16.56, while the 200-day moving average is 17.21.

52-Week Price Change-37.59%
50-Day Moving Average16.56
200-Day Moving Average17.21

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A generated 1.97B in revenue and converted that into 410.62M in net income, yielding earnings per share of 0.74. EBITDA reached 439.94M, while operating income came in at 536.65M.

Revenue1.97B
Gross Profit792.49M
Operating Income536.65M
Pretax Income436.17M
Net Income410.62M
EBITDA439.94M
EBIT439.94M
Earnings Per Share (EPS)0.74

Balance Sheet

CNY

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A holds 537.26M in cash and equivalents against 1.47B in total debt, resulting in a net debt position of 871.46M. Total book value stands at 2.56B, with working capital of 700.70M providing operational flexibility.

Cash & Cash Equivalents537.26M
Total Debt1.47B
Net Debt871.46M
Equity (Book Value)2.56B
Book Value Per Share4.76
Working Capital700.70M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-142.33M

Margins

Over the twelve months ended September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A posted a gross margin of 40.31, reflecting its pricing power and cost economics. The operating margin of 27.30 and net profit margin of 20.89 provide insight into operational efficiency.

Gross Margin40.31
Operating Margin27.30
Pretax Margin22.19
Profit Margin20.89
EBITDA Margin22.38

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of 20.03 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jiangxi Fushine Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio20.03
Shareholder Yield3.06

Stock Splits

Jiangxi Fushine Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 18, 2020 with a 5:8 split ratio.

Last Split Date5/18/2020
Split Ratio5:8

Scores

As of September 30, 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.79